| Heading: |
Pancreatic Enzyme Replacement Therapy |
| Question ID: |
1750759 |
| UIN: |
20760 |
| House: |
Commons |
| Date tabled: |
2024-12-17 |
| Asking Member ID: |
5219 |
| Asking Member display name: |
Mike Martin
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Mike Martin
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of establishing a British supplier of Creon. |
| Is named day: |
true |
| Date of holding answer: |
|
| Date answered: |
2025-01-06 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Department has been working with suppliers to address current supply issues with Creon, which is a brand of pancreatic enzyme replacement therapy (PERT) used by patients with conditions such as cystic fibrosis and certain cancers, including pancreatic... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |